Insulet Azione

Insulet P/E Forward

Il Rapporto P/E Prospettico di Insulet (PODD) al 22 ago 2026 è 65,13. L'anno precedente, Rapporto P/E Prospettico era 38,48 — una variazione del 69,28% (superiore).

P/E Forward

65,13

YoY

69,28%

Ultimo aggiornamento:

Rapporto P/E Prospettico di Insulet ammonta a 2026 65,13 . Rapporto P/E Prospettico di Insulet ammontava a 2025 38,48 . Diminuisce del 69,28% superiore rispetto all'anno precedente.

La storia di Insulet P/E Forward

  • 3 anni

  • 10 anni

  • 25 anni

  • Max

P/E Forward
Date
P/E Forward
1 gen 2018
4889,00 USD
1 gen 2019
1387,47 USD
1 gen 2020
2366,85 USD
1 gen 2021
958,01 USD
1 gen 2022
3498,83 USD
1 gen 2023
78,02 USD
1 gen 2024
38,48 USD
1 gen 2025
65,13 USD
La storia di Insulet P/E Forward
ANNOP/E ForwardYoY
65,13+69,28%
38,48-50,68%
78,02-97,77%
3498,83+265,22%
958,01-59,52%
2366,85+70,59%
1387,47-71,62%
4889,00-915,04%
-599,85+7,63%
-557,31+154,58%
-218,91-29,95%
-312,52
Access this data via the Eulerpool API

Insulet Analisi delle Azioni

Cosa fa Insulet? Insulet Corp is an American company that was founded in 2000 and is headquartered in Acton, Massachusetts. Its goal is to improve the quality of life for people with diabetes by developing innovative products that make living with this chronic disease easier. Insulet Corp is known for its product "OmniPod." The OmniPod is a wireless, portable disposable insulin pump system that offers an alternative option to traditional pumping and insulin delivery systems. The OmniPod system consists of two small devices: a pod worn on the skin and a PDM (Personal Diabetes Manager) that regulates insulin delivery. The pod contains an insulin reservoir that communicates wirelessly with the PDM. The insulin dose is administered directly into the body without needles or tubes. Insulet Corp is also introducing the "OmniPod DASH System." This new system combines the proven design of the OmniPod pod with a new color touchscreen handheld device that allows for even easier operation. The DASH system also offers the ability to control insulin dosing from a smartphone, which can be taken with diabetics wherever they go. The success of the OmniPod system has made Insulet Corp a leading company in the diabetes industry. The company has also developed and introduced products and services in other areas of diabetes treatment. Insulet Corp has developed another product called "Amigo." This product is a personalized travel and training program for people who require insulin. Amigo offers specialized and personalized training to support diabetics in managing complex situations. It also offers diet and exercise plans to make living with diabetes easier. Insulet Corp has also developed a software called "OmniPod Horizon." This software is a closed-loop system that automatically adjusts insulin dosing to keep blood sugar levels within the target range. The system is currently in the development phase and is expected to be released in 2020. Insulet Corp has also developed a program called the "OmniPod Partner Program," which targets doctors and pharmacists. The program provides training and educational materials for healthcare providers to help them better treat and manage their patients. Since 2009, Insulet Corp has been listed on the NASDAQ stock exchange and has continuously evolved since then. The company currently has over 1500 employees and operates in North America, Europe, and the Middle East. Insulet Corp is a company focused on the development of innovative, life-changing products and services. It is expected to continue to play a significant role in improving the quality of life for people with diabetes in the future. Insulet è una delle aziende più popolari su Eulerpool.com.

Domande frequenti su Insulet azioni

Rapporto P/E Prospettico di Insulet è 65,13 nel 2026.

Il Rapporto P/E Prospettico di Insulet è passato da 38,48 a 65,13, con una variazione del 69,28 %. Il valore è superiore rispetto all'anno precedente.

Su Eulerpool è possibile consultare lo sviluppo storico completo del Insulet di Rapporto P/E Prospettico dal 2006, con valori annuali, grafici e analisi dettagliate.

Il P/E prospettico utilizza i guadagni futuri stimati per valutare un'azione. Un P/E prospettico inferiore rispetto al P/E storico suggerisce che gli analisti prevedono crescita degli utili.

Per valutare di Rapporto P/E Prospettico, è essenziale confrontarlo con i competitor nello stesso settore e industria. Su Eulerpool puoi trovare confronti diretti con l'industria per Rapporto P/E Prospettico.

Un 'buono' varia a seconda del settore e della fase di sviluppo dell'azienda. Su Eulerpool puoi confrontare Insulet di Rapporto P/E Prospettico con i competitor del settore e la media industriale per valutare se è attraente.

Access this data via the Eulerpool API

Valutazione — Insulet

Tutte le Metriche Finanziarie — Insulet